Real-world analysis of patients with CLL treated with ibrutinib: a retrospective analysis of Brazilian Registry of CLL
Authors:
- Verena PfisterVPVerena Pfister
- Fernanda de Morais MarquesFMFernanda de Morais Marques
- Talita SilveiraTSTalita Silveira
- Jayr Schmidt FilhoJFJayr Schmidt Filho
- Vinicius Campos de MollaVMVinicius Campos de Molla
- Matheus Vescovi GonçalvesMGMatheus Vescovi Gonçalves
- Mihoko YamamotoMYMihoko Yamamoto
- Rodrigo SantucciRSRodrigo Santucci
- Milton AranhaMAMilton Aranha
- Danielle Leão Cordeiro de FariasDFDanielle Leão Cordeiro de Farias
- Phillip ScheinbergPSPhillip Scheinberg
- Henrique Nunes PêcegoHPHenrique Nunes Pêcego
Open Access
- 18 July 2025
- journal article
- Published by Elsevier in Blood Global Hematology
- Vol. 1 (3)
Abstract
No abstract availableFunding Information
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (001)
- Johnson and Johnson
- Conselho Nacional de Desenvolvimento Científico e Tecnológico (141099/2021-6)
This publication has 36 references indexed in Scilit:
- Ibrutinib (Ibr) dose modification for management of early cardiac adverse events in patients with chronic lymphocytic leukemia: Pooled analysis of 7 clinical trialsHematological Oncology, 2023
- Effectiveness and Safety of Ibrutinib for Chronic Lymphocytic Leukemia in Routine Clinical Practice: 3-Year Follow-up of the Belgian Ibrutinib Real-World Data (BiRD) StudyClinical Hematology International, 2022
- FIRE Study: Real-World Effectiveness and Safety of Ibrutinib in Clinical Practice in Patients with CLL and MCLClinical Hematology International, 2022
- Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic proceduresAmerican Journal of Hematology, 2021
- Real‐world treatment patterns, adverse events and clinical outcomes in patients with chronic lymphocytic leukaemia treated with ibrutinib in the UKeJHaem, 2021
- Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2021
- Outcomes of front‐line ibrutinib treated CLL patients excluded from landmark clinical trialAmerican Journal of Hematology, 2018
- Real‐world results of ibrutinib in relapsed/refractory CLL in France: Early results on a large series of 428 patientsAmerican Journal of Hematology, 2017
- Long‐term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinibCancer, 2017
- Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic LeukemiaJAMA Oncology, 2015